As
filed with the Securities and Exchange Commission on May 28, 2020
Registration
No. 333-
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
S-3
REGISTRATION
STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
Ballantyne
Strong, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
46-5399422
|
(State
or other jurisdiction of
incorporation
or organization)
|
|
(I.R.S.
employer
identification
number)
|
4201
Congress Street, Suite 175
Charlotte,
North Carolina 28209
(704)
994-8279
(Address,
including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Mark
Roberson
Chief Executive Officer
4201 Congress Street, Suite 175
Charlotte,
North Carolina 28209
(704)
994-8279
(Name,
address, including zip code, and telephone number, including area code, of agent for service)
The
Commission is requested to send copies of all communications to:
Joel
L. Rubinstein
Elliott
M. Smith
Winston
& Strawn LLP
200
Park Avenue
New
York, New York 10166
Telephone:
(212) 294-6700
Approximate
date of commencement of proposed sale to the public: From time to time after the effective date of this Registration Statement.
If
the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please
check the following box. [ ]
If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under
the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check
the following box. [X]
If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please
check the following box and list the Securities Act registration statement number of the earlier effective registration statement
for the same offering. [ ]
If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering. [ ]
If
this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become
effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. [ ]
If
this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register
additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following
box. [ ]
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
Large
accelerated filer
|
|
[ ]
|
|
Accelerated
filer
|
|
[ ]
|
Non-accelerated
filer
|
|
[X]
|
|
Smaller
reporting company
|
|
[X]
|
|
|
|
|
Emerging
growth company
|
|
[ ]
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
[ ]
CALCULATION
OF REGISTRATION FEE
Title of Each Class of Securities to be Registered
|
|
Amount
to be
Registered
|
|
Proposed
Maximum Offering
Price Per Unit
|
|
|
Proposed Maximum
Aggregate
Offering Price
|
|
Amount of
Registration Fee(5)
|
|
Common Stock
|
|
(1)(2)
|
|
(1)
|
|
|
(1)(2)
|
|
|
|
|
Preferred Stock
|
|
(1)(2)(3)
|
|
(1)
|
|
|
(1)(2)(3)
|
|
|
|
|
Senior Debt Securities
|
|
(1)(2)(3)
|
|
(1)
|
|
|
(1)(2)(3)
|
|
|
|
|
Subordinated Debt Securities
|
|
(1)(2)(3)
|
|
(1)
|
|
|
(1)(2)(3)
|
|
|
|
|
Depositary Shares
|
|
(1)(2)(3)
|
|
(1)
|
|
|
(1)(2)(3)
|
|
|
|
|
Units(4)
|
|
(1)(2)(3)
|
|
(1)
|
|
|
(1)(2)(3)
|
|
|
|
|
Warrants
|
|
(1)(2)(3)
|
|
(1)
|
|
|
(1)(2)(3)
|
|
|
|
|
Total
|
|
|
|
|
|
$
|
50,000,000
|
|
$
|
6,490
|
|
(1)
|
Not
specified as to each class of securities to be registered pursuant to General Instruction II.D of Form S-3 under the Securities
Act of 1933,
as
amended (the “Securities Act”).
|
(2)
|
The
Registrant is hereby registering an indeterminate principal amount and number of each identified class of its securities up
to a proposed maximum aggregate offering price of $50,000,000, which may be offered from time to time in unspecified numbers
at unspecified prices. The Registrant has estimated the proposed maximum aggregate offering price solely for the purpose of
calculating the registration fee pursuant to Rule 457(o) under the Securities Act. Securities registered hereunder may be
sold separately, together or as units with other securities registered hereunder.
|
(3)
|
The
Registrant is hereby registering such indeterminate amount and number of each identified class of the identified securities
as may be issued upon conversion, exchange, or exercise of any other securities that provide for such conversion, exchange
or exercise.
|
(4)
|
Each
unit will be issued under a unit agreement and will represent an interest in two or more other securities, which may or may
not be separable from one another.
|
(5)
|
Calculated
pursuant to Rule 457(o) under the Securities Act.
|
The
registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until
the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become
effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective
on such date as the Commission, acting pursuant to said Section 8(a), may determine.
The
information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement
filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is
not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
SUBJECT
TO COMPLETION, DATED MAY 28, 2020
PROSPECTUS
$50,000,000
Ballantyne
Strong, Inc.
Common
Stock
Preferred
Stock
Senior
Debt Securities
Subordinated
Debt Securities
Depositary
Shares
Units
Warrants
We
may from time to time offer up to $50,000,000 of the securities listed above in one or more offerings in amounts, at prices and
on terms determined at the time of such offering or offerings. When we use the term “securities” in this prospectus,
we mean any of the securities we may offer with this prospectus, unless we say otherwise.
This
prospectus provides you with a general description of the securities and the general manner in which such securities may be offered.
The specific terms of any securities to be offered, and the specific manner in which they may be offered, will be described in
a supplement to this prospectus or incorporated into this prospectus by reference. You should read this prospectus and any supplement
carefully before you invest. Each prospectus supplement will indicate if the securities offered thereby will be listed or quoted
on a securities exchange or quotation system.
We
may offer and sell the securities described in this prospectus and any prospectus supplement to or through one or more underwriters,
dealers and agents, or directly to purchasers, or through a combination of these methods. If any underwriters, dealers or agents
are involved in the sale of any of the securities, their names and any applicable purchase price, fee, commission or discount
arrangement between or among them will be set forth, or will be calculable from the information set forth, in the applicable prospectus
supplement. See the sections of this prospectus entitled “About this Prospectus” and “Plan of Distribution”
for more information. No securities may be sold without delivery of this prospectus and the applicable prospectus supplement describing
the method and terms of the offering of such securities.
INVESTING
IN OUR SECURITIES INVOLVES RISKS. WE STRONGLY RECOMMEND THAT YOU READ CAREFULLY THE RISKS WE DESCRIBE IN THIS PROSPECTUS AND IN
ANY ACCOMPANYING PROSPECTUS SUPPLEMENT, AS WELL AS THE RISK FACTORS THAT ARE INCORPORATED BY REFERENCE INTO THIS PROSPECTUS FROM
OUR FILINGS MADE WITH THE SECURITIES AND EXCHANGE COMMISSION. SEE “RISK FACTORS” ON PAGE 6 OF THIS PROSPECTUS.
Our
common stock is listed on the NYSE American under the symbol “BTN”. On May 27, 2020 the last reported sale price of
our common stock on the NYSE American was $1.57 per share.
As
of May 27, 2020, the aggregate market value of our outstanding common stock held by non-affiliates was $13,042,488,
based on 14,651,253 shares of outstanding common stock, of which 8,307,317 shares were held by affiliates, and a per
share price of $1.57, based on the closing sale price of our common stock on May 27, 2020. Pursuant to General Instruction I.B.6
of Form S-3, in no event will we sell securities pursuant to this registration statement in a public primary offering with a value
of more than one-third of the aggregate market value of our common stock held by non-affiliates in any 12-month period, so long
as the aggregate market value of our common stock held by non-affiliates is less than $75,000,000. In the event that subsequent
to the effective date of this registration statement, the aggregate market value of our outstanding common stock held by non-affiliates
equals or exceeds $75,000,000, then the one-third limitation on sales shall not apply to additional sales made pursuant to this
registration statement. We have not sold any securities pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar
months prior to, and including, the date of this registration statement.
You
should carefully read this prospectus, any applicable prospectus supplement and the information described under the headings “Where
You Can Find More Information” and “Incorporation by Reference” before you invest in any of these securities.
This prospectus may not be used to sell securities in a primary offering by us unless it is accompanied by a prospectus supplement
that describes the securities being offered.
Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved the securities we may be
offering or determined that this prospectus is accurate or complete. Any representation to the contrary is a criminal offense.
The
date of this prospectus is , 2020
TABLE
OF CONTENTS
ABOUT
THIS PROSPECTUS
This
prospectus is part of a registration statement that we filed with the U.S. Securities and Exchange Commission, or the SEC, using
a “shelf” registration process. By using a shelf registration statement, we may sell securities from time to time
and in one or more offerings up to a total dollar amount of $50,000,000 as described in this prospectus. Each time that we offer
and sell securities, we will provide a prospectus supplement to this prospectus that contains specific information about the securities
being offered and sold and the specific terms of that offering. We may also authorize one or more free writing prospectuses to
be provided to you that may contain material information relating to these offerings. The prospectus supplement or free writing
prospectus may also add, update or change information contained in this prospectus with respect to that offering. If there is
any inconsistency between the information in this prospectus and the applicable prospectus supplement or free writing prospectus,
you should rely on the prospectus supplement or free writing prospectus, as applicable. Before purchasing any securities, you
should carefully read both this prospectus and the applicable prospectus supplement (and any applicable free writing prospectuses),
together with the additional information described under the heading “Where You Can Find More Information; Incorporation
by Reference.”
We
have not authorized any other person to provide you with any information or to make any representations other than those contained
in this prospectus, any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to
which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information
that others may give you. We will not make an offer to sell these securities in any jurisdiction where the offer or sale is not
permitted. You should assume that the information appearing in this prospectus and the applicable prospectus supplement to this
prospectus is accurate only as of the date on its respective cover, that the information appearing in any applicable free writing
prospectus is accurate only as of the date of that free writing prospectus, and that any information incorporated by reference
is accurate only as of the date of the document incorporated by reference, unless we indicate otherwise. Our business, financial
condition, results of operations and prospects may have changed since those dates. This prospectus incorporates by reference,
and any prospectus supplement or free writing prospectus may contain and incorporate by reference, market data and industry statistics
and forecasts that are based on independent industry publications and other publicly available information. Although we believe
these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have not independently
verified this information. In addition, the market and industry data and forecasts that may be included or incorporated by reference
in this prospectus, any prospectus supplement or any applicable free writing prospectus may involve estimates, assumptions and
other risks and uncertainties and are subject to change based on various factors, including those discussed under the heading
“Risk Factors” contained in this prospectus, the applicable prospectus supplement and any applicable free writing
prospectus, and under similar headings in other documents that are incorporated by reference into this prospectus. Accordingly,
investors should not place undue reliance on this information.
Unless
we state otherwise or the context otherwise requires, references in this prospectus to “we,” “our,” “us,”
or “the Company” are to Ballantyne Strong, Inc., a Delaware corporation, together with our consolidated subsidiaries.
CAUTIONARY
STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This
prospectus and the documents incorporated by reference into it contains forward-looking statements regarding the Company and represents
our expectations and beliefs concerning future events that are, or may be considered to be, “forward-looking statements”
within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities
Exchange Act of 1934, as amended, or the Exchange Act. These forward-looking statements are intended to be covered by the safe
harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. The forward-looking statements
included herein or incorporated herein by reference include or may include, but are not limited to, (and you should read carefully)
statements that are predictive in nature, depend upon or refer to future events or conditions, or use or contain words, terms,
phrases, or expressions such as “achieve,” “forecast,” “plan,” “propose,” “strategy,”
“envision,” “hope,” “will,” “continue,” “potential,” “expect,”
“believe,” “anticipate,” “project,” “estimate,” “predict,” “intend,”
“should,” “could,” “may,” “might,” or similar words, terms, phrases, or expressions
or the negative of any of these terms. Any statements in this prospectus or incorporated herein by reference that are not based
upon historical fact are forward-looking statements and represent our best judgment as to what may occur in the future. Forward-looking
statements involve a number of known and unknown risks and uncertainties, including but not limited to those discussed in the
“Risk Factors” section contained in Item 1A in our Annual Report on Form 10-K for the fiscal year ended December 31,
2019 and the following risks and uncertainties: the Company’s ability to maintain and expand its revenue streams, potential
interruptions of supplier relationships or higher prices charged by suppliers, the Company’s ability to successfully compete
and introduce enhancements and new features that achieve market acceptance and that keep pace with technological developments,
the Company’s access to capital, the Company’s ability to successfully execute its capital allocation strategy, the
Company’s ability to maintain its brand and reputation and retain or replace its significant customers, the impact of a
challenging global economic environment or a downturn in the markets (such as the current economic disruption and market volatility
generated by the ongoing COVID-19 pandemic), economic and political risks of selling products in foreign countries (including
tariffs), risks of non-compliance with U.S. and foreign laws and regulations, potential sales tax collections and claims for uncollected
amounts, cybersecurity risks and risks of damage and interruptions of information technology systems, the Company’s ability
to retain key members of management and successfully integrate new executives, the Company’s ability to complete acquisitions,
strategic investments, entry into new lines of business, divestitures, mergers or other transactions on acceptable terms or at
all, the Company’s ability to utilize or assert its intellectual property rights, the impact of natural disasters and other
catastrophic events (such as the ongoing COVID-19 pandemic), the adequacy of insurance and the impact of having a controlling
stockholder. Given the risks and uncertainties, readers should not place undue reliance on any forward-looking statement and should
recognize that the statements are predictions of future results which may not occur as anticipated. Many of the risks listed above
have been, and may be further be, exacerbated by the COVID-19 pandemic, its impact on the cinema and entertainment industry, and
the worsening economic environment.
Although
we believe the expectations reflected in our forward-looking statements are reasonable, in reading this prospectus and the documents
incorporated into this prospectus by reference, you should consider the factors discussed under the heading “Risk Factors”
contained in this prospectus in evaluating any forward-looking statements and you are cautioned not to place undue reliance on
any forward-looking statements. Each forward-looking statement is made and applies only as of the date of the particular statement,
and we are not obligated to update, withdraw, or revise any forward-looking statements, whether as a result of new information,
future events or otherwise. You should consider these risks when reading any forward-looking statements. All forward-looking statements
attributed or attributable to us or to persons acting on our behalf are expressly qualified in their entirety by this section
entitled “Cautionary Statement Regarding Forward-Looking Statements.”
BALLANTYNE
STRONG, INC.
We
are a holding company with diverse business activities focused on serving the entertainment, retail and advertising markets. The
Company and its wholly owned subsidiaries design, integrate and install technology solutions for a broad range of applications;
develop and deliver out-of-home messaging, advertising and communications; manufacture projection screens; and provide managed
services including monitoring of networked equipment to our customers. We add value through our design, engineering, manufacturing
excellence and customer service.
We
conduct our operations through three operating segments: Strong Entertainment, Convergent and Strong Outdoor. Our Strong Entertainment
business is one of the largest manufacturers of premium projection screens. We also manufacture customized screen support systems,
distribute other products and provide technical support services to the cinema, amusement park and other markets. Convergent delivers
digital signage solutions and related services to large multi-location organizations in the United States and Canada. Strong Outdoor
provides outdoor advertising and experiential marketing to advertising agencies and corporate accounts, primarily in New York
City.
We
are a Delaware corporation. Our principal executive offices are located at 4201 Congress Street, Suite 175, Charlotte, North Carolina
28209, and our telephone number at this address is (704) 994-8279. Our website is www.ballantynestrong.com. Information
contained on, or that may be accessible through, our website is not a part of, and is not incorporated into, this prospectus.
RISK
FACTORS
An
investment in our securities involves various risks. Before making an investment in our securities, you should carefully consider
the risks discussed under the heading “Risk Factors” in our most recent Annual Report on Form 10-K, as amended, our
most recent Quarterly Report on Form 10-Q and any subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form
8-K (other than, in each case, information furnished rather than filed), which are incorporated herein by reference, as well as
the information contained in this prospectus and in any prospectus supplements relating to particular offers of securities. Any
of those risk factors could significantly and adversely affect our business, prospects, financial condition and results of operations,
and the trading price of our securities. Although we describe, and will describe, what we believe to be the principal risks related
to our Company and the securities we offer, we can also be affected by risks we do not anticipate or do not think will have a
material effect upon us.
USE
OF PROCEEDS
Unless
otherwise indicated in a prospectus supplement relating to a specific offering, we intend to use the net proceeds from the sale
of securities by us under this prospectus for general corporate purposes, which may include working capital, capital expenditures,
operational purposes and potential acquisitions.
The
intended application of proceeds from the sale of any particular offering of securities using this prospectus will be described
in the accompanying prospectus supplement relating to such offering. The precise amount and timing of the application of these
proceeds will depend on our funding requirements and the availability and costs of other funds.
DESCRIPTION
OF CAPITAL STOCK
The
following summary of the material terms of our securities is not intended to be a complete summary of the rights and preferences
of such securities. We urge you to read our certificate of incorporation (the “Certificate of Incorporation”) and
bylaws (the “Bylaws”) in their entirety for a complete description of the rights and preferences of our securities,
copies of which have been filed with the SEC. These documents are also incorporated by reference into the registration statement
of which this prospectus forms a part.
Authorized
Capital
The
Company’s authorized capital stock consists of 25,000,000 shares of common stock, $0.01 par value per share (the “Common
Stock”), and 1,000,000 shares of preferred stock, $0.01 par value per share (the “Preferred Stock”).
Under
Delaware law, stockholders generally are not personally liable for a corporation’s acts or debts.
Exchange
and Trading Symbol
The
Common Stock is listed for trading on the NYSE American under the trading symbol “BTN.”
Rights
and Preferences
All
outstanding shares of Common Stock are duly authorized, fully paid and nonassessable. Holders of shares of Common Stock have no
conversion, preemptive or subscription rights, and there are no redemption or sinking fund provisions applicable to the Common
Stock. The rights, preferences and privileges of the holders of Common Stock are subject to, and may be adversely affected by,
the rights of the holders of shares of any series of Preferred Stock that the Company may designate and issue in the future.
In
the event of the Company’s liquidation, dissolution or winding up, the holders of Common Stock are entitled to share ratably
in the assets legally available for distribution to stockholders after the payment of all of the Company’s known debts and
liabilities and after adequate provision has been made for each class of stock having preference over the Common Stock, if any.
Voting
Rights
Holders
of Common Stock are entitled to one vote for each share held of record on all matters to be voted on by the stockholders. There
is no cumulative voting with respect to the election of directors. Directors are elected by a plurality of the votes cast by the
holders of Common Stock. Except as otherwise required by law, all other matters brought to a vote of the holders of Common Stock
are determined by a majority of the votes cast and, except as may be provided with respect to any other outstanding class or series
of the Company’s stock, the holders of shares of Common Stock possess the exclusive voting power.
Dividends
Subject
to preferences that may be applicable to any then outstanding shares of Preferred Stock, the holders of Common Stock are entitled
to receive dividends, if any, as may be declared from time to time by the Company’s Board of Directors out of legally available
funds.
Preferred
Stock
The
Board of Directors of the Company is authorized, subject to any limitations prescribed by applicable law and without further approval
or action by the holders of Common Stock, to issue shares of Preferred Stock in one or more series. The Board of Directors may
fix the designation, powers, preferences and rights of the shares of each such series and any qualifications, limitations or restrictions
thereof, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences and sinking
fund terms. The Company has no outstanding shares of Preferred Stock.
The
rights of the holders of Common Stock will generally be subject to the prior rights of the holders of any outstanding shares of
Preferred Stock with respect to dividends, liquidation preferences and other matters.
Anti-Takeover
Effects of Provisions of Delaware Law and the Company’s Certificate of Incorporation and Bylaws
Delaware
Anti-Takeover Law
The
Company is subject to Section 203 of the Delaware General Corporation Law (“Section 203”). Section 203 generally prohibits
a public Delaware corporation from engaging in a “business combination” with an “interested stockholder”
for a period of three years after the date of the transaction in which the person became an interested stockholder unless:
●
|
prior
to the date of the transaction, the board of directors of the corporation approved either the business combination or the
transaction which resulted in the stockholder becoming an interested stockholder;
|
|
|
●
|
upon
consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder
owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for
purposes of determining the number of shares outstanding (but not the outstanding voting stock owned by the interested stockholder)
those shares owned by (i) persons who are directors and also officers and (ii) employee stock plans in which employee participants
do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or
exchange offer; or
|
|
|
●
|
at
or subsequent to such time the business combination is approved by the board of directors and authorized at an annual or special
meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting
stock which is not owned by the interested stockholder.
|
Section
203 defines a “business combination” to generally include:
●
|
any
merger or consolidation of the corporation or any direct or indirect majority-owned subsidiary of the corporation with the
interested stockholder;
|
|
|
●
|
any
sale, lease, exchange, mortgage, pledge, transfer or other disposition (in one transaction or a series of transactions), except
proportionately as a stockholder of such corporation, to or with the interested stockholder of assets of the corporation or
of any direct or indirect majority-owned subsidiary of the corporation which assets have an aggregate market value equal to
10% or more of either the aggregate market value of all the assets of the corporation determined on a consolidated basis or
the aggregate market value of all the outstanding stock of the corporation;
|
|
|
●
|
subject
to certain exceptions, any transaction which results in the issuance or transfer by the corporation or by any direct or indirect
majority-owned subsidiary of the corporation of any stock of the corporation or of such subsidiary to the interested stockholder;
|
|
|
●
|
subject
to certain exceptions, any transaction involving the corporation or any direct or indirect majority-owned subsidiary of the
corporation that has the effect, directly or indirectly, of increasing the interested stockholder’s proportionate share
of the stock of any class or series of securities, or securities convertible into the stock of any class or series, of the
corporation or of any such subsidiary; and
|
|
|
●
|
any
receipt by the interested stockholder of the benefit, directly or indirectly (except proportionately as a stockholder of such
corporation), of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation
or any direct or indirect majority-owned subsidiary.
|
In
general, Section 203 defines an interested stockholder as any entity or person that (i) is the owner of 15% or more of the outstanding
voting stock of the corporation, or (ii) is an affiliate or associate of the corporation and was the owner of 15% or more of the
outstanding voting stock of the corporation at any time within the three-year period immediately prior to the date on which it
is sought to be determined whether such person is an interested stockholder, and the affiliates and associates of such person.
Certificate
of Incorporation and Bylaws
The
Company’s Certificate of Incorporation and Bylaws include anti-takeover provisions that:
●
|
authorize
the Board of Directors, without further action by the stockholders, to issue shares of Preferred Stock in one or more series,
and with respect to each series, to fix the number of shares constituting that series, and establish the rights and terms
of that series;
|
|
|
●
|
establish
advance notice procedures for stockholders to submit nominations of candidates for election to the Board of Directors to be
brought before a stockholders meeting;
|
|
|
●
|
allow
the Company’s directors to establish the size of the Board of Directors and fill vacancies on the Board created by an
increase in the number of directors (subject to the rights of the holders of any series of Preferred Stock to elect additional
directors under specified circumstances);
|
|
|
●
|
require
the affirmative vote of the holders of at least 66 2/3% of the voting power of all of the then-outstanding shares of capital
stock of the Company entitled to vote generally in the election of directors in order to remove a director or the entire Board
of Directors for cause;
|
|
|
●
|
do
not provide stockholders cumulative voting rights with respect to director elections; and
|
|
|
●
|
provide
that the Company’s Bylaws may be amended by the Board of Directors without stockholder approval; provided, however,
that the stockholders may amend the Bylaws only with the affirmative vote of the holders of at least 66 2/3% of the voting
power of all of the then-outstanding shares of capital stock of the Company entitled to vote generally in the election of
directors.
|
Provisions
of the Company’s Certificate of Incorporation and Bylaws may delay or discourage transactions involving an actual or potential
change in the Company’s control or change in the Company’s Board of Directors or management, including transactions
in which stockholders might otherwise receive a premium for their shares or transactions that the Company’s stockholders
might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of the Common
Stock.
Authorized
and Unissued Shares
The
Company’s authorized and unissued shares of Common Stock are available for future issuance without stockholder approval
except as may otherwise be required by applicable stock exchange rules or Delaware law. The Company may issue additional shares
for a variety of purposes, including future offerings to raise additional capital, to fund acquisitions and as employee and consultant
compensation. The existence of authorized but unissued shares of Common Stock could render more difficult, or discourage an attempt,
to obtain control of the Company by means of a proxy contest, tender offer, merger or otherwise.
The
issuance of shares of Preferred Stock by the Company could have certain anti-takeover effects under certain circumstances, and
could enable the Board of Directors to render more difficult or discourage an attempt to obtain control of the Company by means
of a merger, tender offer, or other business combination transaction directed at the Company by, among other things, placing shares
of Preferred Stock with investors who might align themselves with the Board of Directors.
Transfer
Agent and Registrar
The
transfer agent for the shares of the Company’s common stock is Broadridge Financial Solutions, Inc.
DESCRIPTION
OF DEPOSITARY SHARES
We
may issue depositary receipts representing interests, which are called depositary shares, in shares of our common stock or of
particular series of preferred stock. If we did that, we would deposit the common or preferred stock which is the subject of depositary
shares with a depositary, which would hold that common or preferred stock for the benefit of the holders of the depositary shares,
in accordance with a deposit agreement between the depositary and us. The holders of depositary shares would be entitled to all
the rights and preferences of the common or preferred stock to which the depositary shares relate, including dividend, voting,
conversion, redemption and liquidation rights, to the extent of their interests in that common or preferred stock.
While
the deposit agreement relating to common stock or a particular series of preferred stock may have provisions applicable solely
to common stock or that series of preferred stock, all deposit agreements relating to common or preferred stock we issue would
include the following provisions:
Dividends
and Other Distributions. Each time we pay a cash dividend or make any other type of cash distribution with regard to the common
stock or to the preferred stock of a series, the depositary will distribute to the holder of record of each depositary share relating
to that common stock or to that series of preferred stock, an amount equal to the dividend or other distribution per depositary
share the depositary receives. If there is a distribution of property other than cash, the depositary either will distribute the
property to the holders of depositary shares in proportion to the depositary shares held by each of them, or the depositary will,
if we approve, sell the property and distribute the net proceeds to the holders of the depositary shares in proportion to the
depositary shares held by them.
Withdrawal
of Common or Preferred Stock. A holder of depositary shares will be entitled to receive, upon surrender of depositary receipts
representing depositary shares, the number of shares of the applicable common stock or series of preferred stock, and any money
or other property, to which the depositary shares relate.
Redemption
of Depositary Shares. Whenever we redeem shares of a series of preferred stock held by a depositary, the depositary will be
required to redeem, on the same redemption date, depositary shares relating, in total, to the number of shares of that series
held by the depositary which we redeem, subject to the depositary’s receiving the redemption price of those shares. If fewer
than all the depositary shares relating to a series are to be redeemed, the depositary shares to be redeemed will be selected
by lot or by another method we determine to be equitable.
Voting.
Any time we send a notice of meeting or other materials relating to a meeting to the holders of common stock or a series of
preferred stock to which depositary shares relate, we will provide the depositary with sufficient copies of those materials so
they can be sent to all holders of record of the applicable depositary shares, and the depositary will send those materials to
the holders of record of the depositary shares on the record date for the meeting. The depositary will solicit voting instructions
from holders of depositary shares and will vote or not vote the common or preferred stock to which the depositary shares relate
in accordance with those instructions.
Liquidating
Distributions. Upon our liquidation, dissolution or winding up, the holder of each depositary share will be entitled to what
the holder of the depositary share would have received if the holder had owned the number of shares of common stock or of the
series of preferred stock which is represented by the depositary share.
Conversion.
If shares of a series of preferred stock are convertible into common stock or other of our securities or property, holders
of depositary shares relating to that series of preferred stock will, if they surrender depositary receipts representing depositary
shares with appropriate instructions to convert them, receive the shares of common stock or other securities or property into
which the number of shares of the series of preferred stock to which the depositary shares relate could at the time be converted.
Amendment
and Termination of a Deposit Agreement. We and the depositary may amend a deposit agreement, except that an amendment which
materially and adversely affects the rights of holders of depositary shares, or would be materially and adversely inconsistent
with the rights granted to the holders of common stock or the series of preferred stock to which they relate, will have to be
approved by holders of at least two-thirds of the applicable depositary shares. No amendment will impair the right of a holder
of depositary shares to surrender the depositary receipts evidencing those depositary shares and receive the common or preferred
stock to which they relate, except as required to comply with law. We may terminate a deposit agreement with the consent of holders
of a majority of the depositary shares to which it relates. Upon termination of a deposit agreement, the depositary will make
the shares of common or preferred stock to which the depositary shares issued under the deposit agreement relate available to
the holders of those depositary shares. A deposit agreement will automatically terminate if:
|
●
|
all
outstanding depositary shares to which it relates have been withdrawn, redeemed or converted, or
|
|
|
|
|
●
|
the
depositary has made a final distribution to the holders of the depositary shares issued under the deposit agreement upon our
liquidation, dissolution or winding up.
|
Miscellaneous.
There will be provisions (i) requiring the depositary to forward to holders of record of depositary shares any reports or
communications from us which the depositary receives with respect to the common or preferred stock to which the depositary shares
relate, (ii) regarding compensation of the depositary, (iii) regarding resignation of the depositary, (iv) limiting our liability
and the liability of the depositary under the deposit agreement (usually to failure to act in good faith, gross negligence or
willful misconduct) and (v) indemnifying the depositary against certain possible liabilities.
DESCRIPTION
OF DEBT SECURITIES
General
We
will issue the debt securities offered by this prospectus and any accompanying prospectus supplement under an indenture to be
entered into between us and the trustee identified in the applicable prospectus supplement. The terms of the debt securities will
include those stated in the indenture and those made part of the indenture by reference to the Trust Indenture Act of 1939, as
in effect on the date of the indenture. We have filed a copy of the form of indenture as an exhibit to the registration statement
in which this prospectus is included. The indenture will be subject to and governed by the terms of the Trust Indenture Act of
1939.
We
may offer under this prospectus up to an aggregate principal amount of $50,000,000 in debt securities, or if debt securities are
issued at a discount, or in a foreign currency, foreign currency units or composite currency, the principal amount as may be sold
for an aggregate public offering price of up to $50,000,000. Unless otherwise specified in the applicable prospectus supplement,
the debt securities will represent our direct, unsecured obligations and will rank equally with all of our other unsecured indebtedness.
The
debt securities, if and when issued, will be direct, unsecured obligations of our company and may be either senior debt securities
or subordinated debt securities. We may issue debt securities in one or more issuances or series. An indenture, or a supplemental
indenture, will set forth specific terms of each issue or series of debt securities. There will be prospectus supplements relating
to particular issues or series of debt securities. Each prospectus supplement will describe:
|
●
|
the
title of the debt securities and whether the debt securities are senior or subordinated debt securities;
|
|
|
|
|
●
|
the
total principal amount of the debt securities we are offering by that prospectus supplement;
|
|
|
|
|
●
|
the
date or dates on which principal of the debt securities will be payable and the amount of principal which will be payable;
|
|
|
|
|
●
|
the
rate or rates (which may be fixed or variable) at which the debt securities will bear interest, if any, or contingent interest,
if any, as well as the dates from which interest will accrue, the dates on which interest will be payable, the persons to
whom interest will be payable, if other than the registered holders on the record date, and the record date for the interest
payable on any payment date;
|
|
|
|
|
●
|
the
currency in which principal and interest, and any premium, will be payable;
|
|
|
|
|
●
|
the
place or places where principal, premium, if any, and interest, if any, on the debt securities will be payable and where debt
securities which are in registered form can be presented for registration of transfer or exchange;
|
|
|
|
|
●
|
any
provisions regarding our right to prepay debt securities or of holders to require us to prepay debt securities;
|
|
|
|
|
●
|
the
right, if any, of holders of the debt securities to convert them into common stock or other securities, including any contingent
conversion provisions;
|
|
|
|
|
●
|
any
provisions requiring or permitting us to make payments to a sinking fund which will be used to redeem debt securities or a
purchase fund which will be used to purchase debt securities;
|
|
|
|
|
●
|
the
percentage of the principal amount of the debt securities which is payable if maturity of the debt securities is accelerated
because of a default;
|
|
|
|
|
●
|
any
special or modified events of default or covenants with respect to the debt securities; and
|
|
|
|
|
●
|
any
other material terms of the debt securities.
|
We
may issue discount debt securities that provide for an amount less than the stated principal amount to be due and payable upon
acceleration of the maturity of such debt securities in accordance with the terms of the indenture. We may also issue debt securities
in bearer form, with or without coupons. If we issue discount debt securities or debt securities in bearer form, we will describe
material U.S. federal income tax considerations and other material special considerations which apply to these debt securities
in the applicable prospectus supplement.
We
may issue debt securities denominated in or payable in a foreign currency or currencies or a foreign currency unit or units. If
we do, we will describe the restrictions, elections, and general tax considerations relating to the debt securities and the foreign
currency or currencies or foreign currency unit or units in the applicable prospectus supplement.
Registrar
and Paying Agent
The
debt securities may be presented for registration of transfer or for exchange at the corporate trust office of the security registrar
or at any other office or agency that we maintain for those purposes. In addition, the debt securities may be presented for payment
of principal, interest and any premium at the office of the paying agent or at any office or agency that we maintain for those
purposes.
Conversion
or Exchange Rights
Debt
securities may be convertible into or exchangeable for shares of our common stock. The terms and conditions of conversion or exchange
will be stated in the applicable prospectus supplement. The terms will include, among others, the following:
|
●
|
the
conversion or exchange price;
|
|
|
|
|
●
|
the
conversion or exchange period;
|
|
|
|
|
●
|
provisions
regarding the convertibility or exchangeability of the debt securities, including who may convert or exchange;
|
|
|
|
|
●
|
events
requiring adjustment to the conversion or exchange price;
|
|
|
|
|
●
|
provisions
affecting conversion or exchange in the event of our redemption of the debt securities; and
|
|
|
|
|
●
|
any
anti-dilution provisions, if applicable.
|
Registered
Global Securities
If
we decide to issue debt securities in the form of one or more global securities, then we will register the global securities in
the name of the depositary for the global securities or the nominee of the depositary, and the global securities will be delivered
by the trustee to the depositary for credit to the accounts of the holders of beneficial interests in the debt securities.
The
prospectus supplement will describe the specific terms of the depositary arrangement for debt securities of a series that are
issued in global form. None of us, the trustee, any payment agent or the security registrar will have any responsibility or liability
for any aspect of the records relating to or payments made on account of beneficial ownership interests in a global debt security
or for maintaining, supervising or reviewing any records relating to these beneficial ownership interests.
No
Protection in the Event of a Change of Control
The
indenture does not have any covenants or other provisions providing for a put or increased interest or otherwise that would afford
holders of our debt securities additional protection in the event of a recapitalization transaction, a change of control or a
highly leveraged transaction. If we offer any covenants or provisions of this type with respect to any debt securities covered
by this prospectus, we will describe them in the applicable prospectus supplement.
Covenants
Unless
otherwise indicated in this prospectus or the applicable prospectus supplement, our debt securities will not have the benefit
of any covenants that limit or restrict our business or operations, the pledging of our assets or the incurrence by us of indebtedness.
We will describe in the applicable prospectus supplement any material covenants in respect of a series of debt securities.
Merger,
Consolidation or Sale of Asset
The
form of indenture provides that we will not consolidate with or merge into any other person or convey, transfer, sell or lease
our properties and assets substantially as an entirety to any person, unless:
|
●
|
we
are the surviving person of such merger or consolidation, or if we are not the surviving person, the person formed by the
consolidation or into or with which we are merged or the person to which our properties and assets are conveyed, transferred,
sold or leased, is a corporation organized and existing under the laws of the U.S., any state or the District of Columbia
or a corporation or comparable legal entity organized under the laws of a foreign jurisdiction and has expressly assumed all
of our obligations, including the payment of the principal of and, premium, if any, and interest on the debt securities and
the performance of the other covenants under the indenture; and
|
|
●
|
immediately
before and immediately after giving effect to the transaction on a pro forma basis, no event of default, and no event which,
after notice or lapse of time or both, would become an event of default, has occurred and is continuing under the indenture.
|
Events
of Default and Remedies
Unless
otherwise specified in the applicable prospectus supplement, the following events will be events of default under the indenture
with respect to debt securities of any series:
|
●
|
we
fail to pay any principal or premium, if any, when it becomes due;
|
|
|
|
|
●
|
we
fail to pay any interest within 30 days after it becomes due;
|
|
|
|
|
●
|
we
fail to observe or perform any other covenant in the debt securities or the indenture for 60 days after written notice specifying
the failure from the trustee or the holders of not less than 25% in aggregate principal amount of the outstanding debt securities
of that series; and
|
|
|
|
|
●
|
certain
events involving bankruptcy, insolvency or reorganization of us or any of our significant subsidiaries.
|
The
trustee may withhold notice to the holders of the debt securities of any series of any default, except in payment of principal
of or premium, if any, or interest on the debt securities of a series, if the trustee considers it to be in the best interest
of the holders of the debt securities of that series to do so.
If
an event of default (other than an event of default resulting from certain events of bankruptcy, insolvency or reorganization)
occurs, and is continuing, then the trustee or the holders of not less than 25% in aggregate principal amount of the outstanding
debt securities of any series may accelerate the maturity of the debt securities. If this happens, the entire principal amount,
plus the premium, if any, of all the outstanding debt securities of the affected series plus accrued interest to the date of acceleration
will be immediately due and payable. At any time after the acceleration, but before a judgment or decree based on such acceleration
is obtained by the trustee, the holders of a majority in aggregate principal amount of outstanding debt securities of such series
may rescind and annul such acceleration if:
|
●
|
all
events of default (other than nonpayment of accelerated principal, premium or interest) have been cured or waived;
|
|
|
|
|
●
|
all
lawful interest on overdue interest and overdue principal has been paid; and
|
|
|
|
|
●
|
the
rescission would not conflict with any judgment or decree.
|
In
addition, if the acceleration occurs at any time when we have outstanding indebtedness that is senior to the debt securities,
the payment of the principal amount of outstanding debt securities may be subordinated in right of payment to the prior payment
of any amounts due under the senior indebtedness, in which case the holders of debt securities will be entitled to payment under
the terms prescribed in the instruments evidencing the senior indebtedness and the indenture.
If
an event of default resulting from certain events of bankruptcy, insolvency or reorganization occurs, the principal, premium and
interest amount with respect to all of the debt securities of any series will be due and payable immediately without any declaration
or other act on the part of the trustee or the holders of the debt securities of that series.
The
holders of a majority in principal amount of the outstanding debt securities of a series will have the right to waive any existing
default or compliance with any provision of the indenture or the debt securities of that series and to direct the time, method
and place of conducting any proceeding for any remedy available to the trustee, subject to certain limitations specified in the
indenture.
No
holder of any debt security of a series will have any right to institute any proceeding with respect to the indenture or for any
remedy under the indenture, unless:
|
●
|
the
holder gives to the trustee written notice of a continuing event of default;
|
|
|
|
|
●
|
the
holders of at least 25% in aggregate principal amount of the outstanding debt securities of the affected series make a written
request and offer reasonable indemnity to the trustee to institute a proceeding as trustee;
|
|
|
|
|
●
|
the
trustee fails to institute a proceeding within 60 days after such request; and
|
|
|
|
|
●
|
the
holders of a majority in aggregate principal amount of the outstanding debt securities of the affected series do not give
the trustee a direction inconsistent with such request during such 60-day period.
|
These
limitations do not, however, apply to a suit instituted for payment on debt securities of any series on or after the due dates
expressed in the debt securities.
We
will periodically deliver certificates to the trustee regarding our compliance with our obligations under the indenture.
Modification
of an Indenture
From
time to time, we and the trustee may, without the consent of holders of the debt securities of one or more series, amend the indenture
or the debt securities of one or more series, or supplement the indenture, for certain specified purposes, including:
|
●
|
to
provide that the surviving entity following a change of control permitted under the indenture will assume all of our obligations
under the indenture and debt securities;
|
|
|
|
|
●
|
to
provide for certificated debt securities in addition to uncertificated debt securities;
|
|
|
|
|
●
|
to
comply with any requirements of the SEC under the Trust Indenture Act of 1939;
|
|
|
|
|
●
|
to
provide for the issuance of and establish the form and terms and conditions of debt securities of any series as permitted
by the indenture;
|
|
|
|
|
●
|
to
cure any ambiguity, defect or inconsistency, or make any other change that does not materially and adversely affect the rights
of any holder; and
|
|
|
|
|
●
|
to
appoint a successor trustee under the indenture with respect to one or more series.
|
From
time to time we and the trustee may, with the consent of holders of at least a majority in principal amount of an outstanding
series of debt securities, amend or supplement the indenture or the debt securities series, or waive compliance in a particular
instance by us with any provision of the indenture or the debt securities. We may not, however, without the consent of each holder
affected by such action, modify or supplement the indenture or the debt securities or waive compliance with any provision of the
indenture or the debt securities in order to:
|
●
|
reduce
the amount of debt securities whose holders must consent to an amendment, supplement, or waiver to the indenture or such debt
security;
|
|
|
|
|
●
|
reduce
the rate of or change the time for payment of interest or reduce the amount of or postpone the date for payment of sinking
fund or analogous obligations;
|
|
|
|
|
●
|
reduce
the principal of or change the stated maturity of the debt securities;
|
|
|
|
|
●
|
make
any debt security payable in money other than that stated in the debt security;
|
|
|
|
|
●
|
change
the amount or time of any payment required or reduce the premium payable upon any redemption, or change the time before which
no such redemption may be made;
|
|
|
|
|
●
|
waive
a default in the payment of the principal of, premium, if any, or interest on the debt securities or a redemption payment;
|
|
|
|
|
●
|
waive
a redemption payment with respect to any debt securities or change any provision with respect to redemption of debt securities;
or
|
|
|
|
|
●
|
take
any other action otherwise prohibited by the indenture to be taken without the consent of each holder affected by the action.
|
Defeasance
of Debt Securities and Certain Covenants in Certain Circumstances
The
indenture permits us, at any time, to elect to discharge our obligations with respect to one or more series of debt securities
by following certain procedures described in the indenture. These procedures will allow us either:
|
●
|
to
defease and be discharged from any and all of our obligations with respect to any debt securities except for the following
obligations (which discharge is referred to as “legal defeasance”);
|
|
|
|
|
●
|
to
register the transfer or exchange of such debt securities;
|
|
|
|
|
●
|
to
replace temporary or mutilated, destroyed, lost or stolen debt securities;
|
|
|
|
|
●
|
to
compensate and indemnify the trustee;
|
|
|
|
|
●
|
to
maintain an office or agency in respect of the debt securities and to hold monies for payment in trust; or
|
|
|
|
|
●
|
to
be released from our obligations with respect to the debt securities under certain covenants contained in the indenture, as
well as any additional covenants which may be contained in the applicable supplemental indenture (which release is referred
to as “covenant defeasance”).
|
In
order to exercise either defeasance option, we must irrevocably deposit with the trustee or other qualifying trustee, in trust
for that purpose:
|
●
|
money;
|
|
|
|
|
●
|
U.S.
Government Obligations (as described below) or Foreign Government Obligations (as described below) that through the scheduled
payment of principal and interest in accordance with their terms will provide money; or
|
|
|
|
|
●
|
a
combination of money and/or U.S. Government Obligations and/or Foreign Government Obligations sufficient in the written opinion
of a nationally-recognized firm of independent accountants to provide money;
|
that,
in each case specified above, provides a sufficient amount to pay the principal of, premium, if any, and interest, if any, on
the debt securities of the series, on the scheduled due dates or on a selected date of redemption in accordance with the terms
of the indenture.
In
addition, defeasance may be effected only if, among other things:
|
●
|
in
the case of either legal or covenant defeasance, we deliver to the trustee an opinion of counsel, as specified in the indenture,
stating that as a result of the defeasance neither the trust nor the trustee will be required to register as an investment
company under the Investment Company Act of 1940;
|
|
|
|
|
●
|
in
the case of legal defeasance, we deliver to the trustee an opinion of counsel stating that we have received from, or there
has been published by, the Internal Revenue Service a ruling to the effect that, or there has been a change in any applicable
federal income tax law with the effect that (and the opinion shall confirm that), the holders of outstanding debt securities
will not recognize income, gain or loss for U.S. federal income tax purposes solely as a result of such legal defeasance and
will be subject to U.S. federal income tax on the same amounts, in the same manner, including as a result of prepayment, and
at the same times as would have been the case if legal defeasance had not occurred;
|
|
|
|
|
●
|
in
the case of covenant defeasance, we deliver to the trustee an opinion of counsel to the effect that the holders of the outstanding
debt securities will not recognize income, gain or loss for U.S. federal income tax purposes as a result of covenant defeasance
and will be subject to U.S. federal income tax on the same amounts, in the same manner and at the same times as would have
been the case if covenant defeasance had not occurred; and
|
|
|
|
|
●
|
certain
other conditions described in the indenture are satisfied.
|
If
we fail to comply with our remaining obligations under the indenture and applicable supplemental indenture after a covenant defeasance
of the indenture and applicable supplemental indenture, and the debt securities are declared due and payable because of the occurrence
of any undefeased event of default, the amount of money or U.S. Government Obligations or Foreign Government Obligations on deposit
with the trustee could be insufficient to pay amounts due under the debt securities of the affected series at the time of acceleration.
We will, however, remain liable in respect of these payments.
The
term “U.S. Government Obligations” as used in the above discussion means securities that are direct obligations of
or non-callable obligations guaranteed by the United States of America for the payment of which obligation or guarantee the full
faith and credit of the United States of America is pledged.
The
term “Foreign Government Obligations” as used in the above discussion means, with respect to debt securities of any
series that are denominated in a currency other than U.S. dollars, (1) direct obligations of the government that issued or caused
to be issued such currency for the payment of which obligations its full faith and credit is pledged or (2) obligations of a person
controlled or supervised by or acting as an agent or instrumentality of such government the timely payment of which is unconditionally
guaranteed as a full faith and credit obligation by that government, which in either case under clauses (1) or (2), are not callable
or redeemable at the option of the issuer.
Regarding
the Trustee
We
will identify the trustee with respect to any series of debt securities in the prospectus supplement relating to the applicable
debt securities. You should note that if the trustee becomes a creditor of ours, the indenture and the Trust Indenture Act of
1939 limit the rights of the trustee to obtain payment of claims in certain cases, or to realize on certain property received
in respect of any such claim, as security or otherwise. The trustee and its affiliates may engage in, and will be permitted to
continue to engage in, other transactions with us and our affiliates. If, however, the trustee acquires any “conflicting
interest” within the meaning of the Trust Indenture Act of 1939, it must eliminate such conflict or resign.
The
holders of a majority in principal amount of the then outstanding debt securities of any series may direct the time, method and
place of conducting any proceeding for exercising any remedy available to the trustee. If an event of default occurs and is continuing,
the trustee, in the exercise of its rights and powers, must use the degree of care and skill of a prudent person in the conduct
of his or her own affairs. Subject to that provision, the trustee will be under no obligation to exercise any of its rights or
powers under the indenture at the request of any of the holders of the debt securities, unless they have offered to the trustee
reasonable indemnity or security.
No
Individual Liability of Incorporators, Stockholders, Officers or Directors
Each
indenture provides that no incorporator and no past, present or future stockholder, officer or director of our Company or any
successor corporation in those capacities will have any individual liability for any of our obligations, covenants or agreements
under the debt securities or such indenture.
Governing
Law
The
indentures and the debt securities will be governed by, and construed in accordance with, the laws of the State of New York.
DESCRIPTION
OF WARRANTS
We
may issue warrants to purchase common stock, preferred stock, depositary shares, debt securities or units. Each issue of warrants
will be the subject of a warrant agreement which will contain the terms of the warrants. In the event that we issue warrants,
we will distribute a prospectus supplement with regard to each issue of warrants. Each prospectus supplement will describe, as
to the warrants to which it relates:
|
●
|
the
securities which may be purchased by exercising the warrants (which may be common stock, preferred stock, depositary shares,
debt securities or units consisting of two or more of those types of securities);
|
|
|
|
|
●
|
the
exercise price of the warrants (which may be wholly or partly payable in cash or wholly or partly payable with other types
of consideration);
|
|
|
|
|
●
|
the
period during which the warrants may be exercised;
|
|
|
|
|
●
|
any
provision adjusting the securities which may be purchased on exercise of the warrants and the exercise price of the warrants
in order to prevent dilution or otherwise;
|
|
|
|
|
●
|
the
place or places where warrants can be presented for exercise or for registration of transfer or exchange; and
|
|
|
|
|
●
|
any
other material terms of the warrants.
|
Exercise
of Warrants
Each
warrant will entitle the holder of the warrant to purchase for cash the amount of common stock, preferred stock, depositary shares,
debt securities or units at the exercise price stated or determinable in the applicable prospectus supplement for the warrants.
Warrants may be exercised at any time up to the close of business on the expiration date shown in the applicable prospectus supplement,
unless otherwise specified in such prospectus supplement. After the close of business on the expiration date, unexercised warrants
will become void. Warrants may be exercised as described in the applicable prospectus supplement.
Until
a holder exercises the warrants to purchase any securities underlying the warrants, the holder will not have any rights as a holder
of the underlying securities by virtue of ownership of warrants.
DESCRIPTION
OF UNITS
We
may issue securities in units, each consisting of two or more types of securities. For example, we might issue units consisting
of a combination of debt securities and warrants to purchase common stock. If we issue units, the prospectus supplement relating
to the units will contain the information described above with regard to each of the securities that is a component of the units.
In addition, each prospectus supplement relating to units will:
|
●
|
state
how long, if at all, the securities that are components of the units must be traded in units, and when they can be traded
separately;
|
|
|
|
|
●
|
state
whether we will apply to have the units traded on a securities exchange or securities quotation system; and
|
|
|
|
|
●
|
describe
how, for U.S. federal income tax purposes, the purchase price paid for the units is to be allocated among the component securities.
|
PLAN
OF DISTRIBUTION
We
may sell the securities offered through this prospectus and applicable prospectus supplements in one or more of the following
ways from time to time: (i) to or through underwriters or dealers, (ii) directly to one or more purchasers, including our affiliates,
(iii) through agents, (iv) through a combination of any these methods, or (v) through any other method permitted by applicable
law.
In
addition, the manner in which we may sell some or all of the securities covered by this prospectus, includes, without limitation,
through:
|
●
|
an
“at the market” offering, within the meaning of Rule 415(a)(4) of the Securities Act of 1933, as amended, or the
“Securities Act,” to or through a market maker or into an existing trading market on an exchange or otherwise;
|
|
|
|
|
●
|
a
block trade in which a broker-dealer will attempt to sell as agent, but may position or resell a portion of the block, as
principal, in order to facilitate the transaction;
|
|
|
|
|
●
|
purchases
by a broker-dealer, as principal, and resale by the broker-dealer for its account;
|
|
|
|
|
●
|
ordinary
brokerage transactions and transactions in which a broker solicits purchasers; or
|
|
|
|
|
●
|
privately
negotiated transactions.
|
The
securities may be distributed at a fixed price or prices, which may be changed, based on market prices prevailing at the time
of sale, prices related to the prevailing market prices, or negotiated prices. The prospectus supplement relating to an offering
of securities will set forth the terms of such offering, including:
|
●
|
the
name or names of any underwriters or agents;
|
|
|
|
|
●
|
the
name or names of any managing underwriter or underwriters;
|
|
|
|
|
●
|
the
name or names of any broker/dealers or placement agents;
|
|
|
|
|
●
|
the
purchase price of the securities;
|
|
|
|
|
●
|
any
over-allotment options under which underwriters may purchase additional securities;
|
|
|
|
|
●
|
the
net proceeds from the sale of the securities;
|
|
|
|
|
●
|
any
delayed delivery arrangements;
|
|
|
|
|
●
|
any
underwriting discounts, commissions and other items constituting underwriters’ compensation;
|
|
|
|
|
●
|
any
initial public offering price;
|
|
|
|
|
●
|
any
discounts or concessions allowed or reallowed or paid to dealers;
|
|
|
|
|
●
|
any
commissions paid to agents; and
|
|
|
|
|
●
|
any
securities exchange or market on which the securities may be listed.
|
Sale
Through Underwriters or Dealers
Only
underwriters named in a prospectus supplement are underwriters of the securities offered by such prospectus supplement.
If
underwriters are used in the sale, the underwriters will acquire the securities for their own account, including through underwriting,
purchase, security lending or repurchase agreements with us. The underwriters may resell the securities from time to time in one
or more transactions, including negotiated transactions. Underwriters may sell the securities in order to facilitate transactions
in any of our other securities (described in this prospectus or otherwise), including other public or private transactions and
short sales. Underwriters may offer securities to the public either through underwriting syndicates represented by one or more
managing underwriters or directly by one or more firms acting as underwriters without a syndicate. Unless otherwise indicated
in a prospectus supplement, the obligations of the underwriters to purchase the securities will be subject to certain conditions,
and the underwriters will be obligated to purchase all the offered securities if they purchase any of them. The underwriters may
change from time to time any public offering price and any discounts or concessions allowed or reallowed or paid to dealers.
If
dealers are used in the sale of securities offered through this prospectus, we will sell the securities to them as principals.
The dealers may then resell those securities to the public at varying prices determined by the dealers at the time of resale.
The prospectus supplement will include the names of the dealers and the terms of the transaction.
The
maximum compensation or discount to be received by any FINRA member or independent broker-dealer will not be greater than 8% for
the sale of any securities being registered hereunder pursuant to Rule 415 of the Securities Act.
Direct
Sales and Sales Through Agents
We
may sell the securities offered through this prospectus directly. In this case, no underwriters or agents would be involved. Such
securities may also be sold through agents designated from time to time. Any applicable prospectus supplement will name any agent
involved in the offer or sale of the offered securities and will describe any commissions payable to the agent. Unless otherwise
indicated in the prospectus supplement, any agent will agree to use its reasonable best efforts to solicit purchases for the period
of its appointment.
We
may sell the securities directly to institutional investors or others who may be deemed to be underwriters within the meaning
of the Securities Act with respect to any sale of those securities. The terms of any such sales will be described in a prospectus
supplement.
Delayed
Delivery Contracts
If
an applicable prospectus supplement indicates, we may authorize agents, underwriters or dealers to solicit offers from certain
types of institutions to purchase securities at the public offering price under delayed delivery contracts. These contracts would
provide for payment and delivery on a specified date in the future. The contracts would be subject only to those conditions described
in the prospectus supplement. The applicable prospectus supplement will describe the commission payable for solicitation of those
contracts.
Market
Making, Stabilization and Other Transactions
We
may elect to list offered securities on an exchange or in the over-the-counter market. Any underwriters that we use in the sale
of offered securities may make a market in such securities, but may discontinue such market making at any time without notice.
Therefore, we cannot assure you that the securities will have a liquid trading market.
Certain
persons participating in an offering may engage in overallotment, stabilizing transactions, syndicate covering transactions and
penalty bids in accordance with rules and regulations under the Exchange Act. Overallotment involves the sale in excess of the
offering size, which create a short position. Stabilizing transactions involve bids to purchase the underlying security in the
open market for the purpose of pegging, fixing or maintaining the price of the securities. Syndicate covering transactions involve
purchases of the securities in the open market after the distribution has been completed in order to cover syndicate short positions.
Penalty
bids permit the underwriters to reclaim a selling concession from a syndicate member when the securities originally sold by the
syndicate member are purchased in a syndicate covering transaction to cover syndicate short positions. Stabilizing transactions,
syndicate covering transactions and penalty bids may cause the price of the securities to be higher than it would be in the absence
of the transactions. The underwriters may, if they commence these transactions, discontinue them at any time.
General
Information
Agents,
underwriters, and dealers may be entitled, under agreements entered into with us, to indemnification by us against certain liabilities,
including liabilities under the Securities Act. Our agents, underwriters, and dealers, or their affiliates, may be customers of,
engage in transactions with or perform services for us in the ordinary course of business.
LEGAL
MATTERS
Winston
& Strawn LLP, New York, New York, or other counsel selected by the Company with regard to a particular offering, who will
be named in the prospectus supplement relating to that offering, will pass upon the validity of any securities we offer by this
prospectus. If the validity of any securities is also passed upon by counsel for the underwriters of an offering of those securities,
that counsel will be named in the prospectus supplement relating to that offering.
EXPERTS
The
consolidated financial statements of the Company as of December 31, 2019 and for the year ended December 31, 2019, incorporated
in this prospectus by reference to the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, have been
so incorporated in reliance on the report of Haskell & White LLP, an independent registered public accounting firm,
incorporated herein by reference, given on the authority of said firm as experts in accounting and auditing.
The
consolidated financial statements as of December 31, 2018 and for the year then ended incorporated by reference in this
prospectus have been so incorporated in reliance on the report of BDO USA, LLP, an independent registered public accounting
firm, incorporated herein by reference, given on the authority of said firm as experts in auditing and accounting.
WHERE
YOU CAN FIND MORE INFORMATION
We
are subject to the information reporting requirements of the Exchange Act and, in accordance with these requirements, we file
annual, quarterly and current reports, proxy statements, information statements, and other information with the SEC. Our SEC filings
are available to the public over the Internet at the SEC’s website at www.sec.gov. In addition, we provide free access to
these materials through our website, www.ballantynestrong.com, as soon as reasonably practicable after they are filed with or
furnished to the SEC. Information contained on, or that may be accessible through, our website is not a part of, and is not incorporated
into, this prospectus.
We
have filed with the SEC a registration statement on Form S-3 relating to the securities covered by this prospectus and any prospectus
supplement. This prospectus is a part of the registration statement and does not contain all the information in the registration
statement. Whenever a reference is made in this prospectus or any prospectus supplement to a contract or other document, the reference
is only a summary and you should refer to the exhibits that are a part of the registration statement for a copy of the contract
or other document. You may review a copy of the registration statement through the SEC’s website.
INCORPORATION
BY REFERENCE
The
SEC allows us to incorporate by reference information in this document. This means that we can disclose important information
to you by referring you to documents that we have previously filed with the SEC or documents that we will file with the SEC in
the future. The information incorporated by reference is considered to be an important part of this prospectus, except for any
information that is superseded by information that is included directly in this document.
We
are incorporating by reference in this prospectus the following documents which we have previously filed with the SEC (other than
any portions of the Current Reports on Form 8-K that were furnished pursuant to Item 2.02 or 7.01 of Form 8-K or other applicable
SEC rules):
(1)
|
Annual
Report on Form 10-K for the year ended December 31, 2019, filed on March 16, 2020 (File No. 001-13906) and Amendment No. 1
to the Annual Report on Form 10-K for the year ended December 31, 2019, filed on April 20, 2020 (File No. 001-13906);
|
(2)
|
Quarterly
Report on Form 10-Q for the quarter ended March 31, 2020, filed on May 12, 2020 (File No. 001-13906);
|
|
|
(3)
|
Current
Reports on Form 8-K filed on March 16, 2020, April 16, 2020, April 24, 2020 and April 30, 2020 (File Nos. 001-13906); and
|
|
|
(4)
|
the
description of our shares of common stock contained in our Registration Statement on Form 8-A, as filed with the SEC on September
22, 2004 (File No. 001-13906), including any amendment or report filed for the purpose of updating such description.
|
Whenever
after the date of filing the registration statement of which this prospectus is a part, and until all of the securities to which
this prospectus relates have been sold or the offering is otherwise terminated, we file reports or documents under Section 13(a),
13(c), 14 or 15(d) of the Exchange Act, those reports and documents will be deemed to be part of this prospectus from the time
they are filed. Any statements made in this prospectus or in a document incorporated or deemed to be incorporated by reference
in this prospectus will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement
contained in this prospectus or in any subsequently filed document that is also incorporated or deemed to be incorporated by reference
in this prospectus modifies or supersedes the statement. Nothing in this prospectus will be deemed to incorporate information
furnished by us on Form 8-K that under the rules of the SEC, is not deemed “filed” for purposes of the Exchange Act.
You
may request, without charge, a copy of any incorporated document (excluding exhibits, unless we have specifically incorporated
an exhibit in an incorporated document) by writing or telephoning us at our principal executive offices at the following address:
Ballantyne
Strong, Inc.
Attention:
Investor Relations
4201
Congress Street, Suite 175
Charlotte,
North Carolina 28209
(704)
994-8279
$50,000,000
Ballantyne
Strong, Inc.
Common
Stock
Preferred
Stock
Senior
Debt Securities
Subordinated
Debt Securities
Depositary
Shares
Units
Warrants
PROSPECTUS
PART
II
INFORMATION
NOT REQUIRED IN PROSPECTUS
Item
14. Other Expenses of Issuance and Distribution
The
following table sets forth the various costs and expenses to be paid by us in connection with the sale and distribution of the
securities being registered, other than underwriting discounts and commissions. All amounts shown are estimates except for the
registration fee required by the Securities & Exchange Commission (“SEC”).
SEC registration
fee
|
|
$
|
6,490
|
|
Accounting fees and
expenses
|
|
|
(1
|
)
|
FINRA filing fees
|
|
|
(1
|
)
|
Legal fees and expenses
|
|
|
(1
|
)
|
Fees and expenses of
the trustee
|
|
|
(1
|
)
|
Transfer agent fees
and expenses
|
|
|
(1
|
)
|
Depositary fees and
expenses
|
|
|
(1
|
)
|
Warrant agent fees
and expenses
|
|
|
(1
|
)
|
Printing expenses
|
|
|
(1
|
)
|
Miscellaneous
|
|
|
(1
|
)
|
Total
|
|
|
(1
|
)
|
|
(1)
|
These
fees are calculated based on the securities offered and the number of issuances and accordingly cannot be estimated at this
time.
|
Item 15. Indemnification of Directors and Officers
Section
145 of the Delaware General Corporation Law provides, in summary, that directors and officers of Delaware corporations are entitled,
under certain circumstances, to be indemnified against all expenses and liabilities (including attorneys’ fees) incurred
by them as a result of suits brought against them in their capacity as a director or officer, if they acted in good faith and
in a manner they reasonably believed to be in or not opposed to our best interests, and, with respect to any criminal action or
proceeding, if they had no reasonable cause to believe their conduct was unlawful; provided that no indemnification may be made
against expenses in respect of any claim, issue or matter as to which they shall have been adjudged to be liable to us, unless
and only to the extent that the court in which such action or suit was brought shall determine upon application that, despite
the adjudication of liability but in view of all the circumstances of the case, they are fairly and reasonably entitled to indemnity
for such expenses which the court shall deem proper. Any such indemnification may be made by us only as authorized in each specific
case upon a determination by the stockholders, disinterested directors or independent legal counsel that indemnification is proper
because the indemnitee has met the applicable standard of conduct.
Our
Bylaws, as amended, provides that our directors and officers will be indemnified by us to the fullest extent authorized by Delaware
General Corporation Law as it now exists or may in the future be amended.
We
may in the future enter into agreements with our directors to provide contractual indemnification in addition to the indemnification
provided in our Bylaws. Our Bylaws also permit us to secure insurance on behalf of any officer, director, employee or agent for
any liability arising out of his or her actions, regardless of whether the bylaws or Delaware General Corporation Law would permit
indemnification. We have purchased a policy of directors’ and officers’ liability insurance that insures our directors
and officers against the cost of defense, settlement or payment of a judgment in some circumstances and insures us against our
obligations to indemnify the directors and officers.
These
provisions may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. These
provisions also may have the effect of reducing the likelihood of derivative litigation against directors and officers, even though
such an action, if successful, might otherwise benefit us and our stockholders. Furthermore, a stockholder’s investment
may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant
to these indemnification provisions. We believe that these provisions, the insurance and the indemnity agreements are necessary
to attract and retain talented and experienced directors and officers.
Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling
persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC, such indemnification
is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
Item
16. Exhibits
Exhibit
Number
|
|
Description
|
1.1*
|
|
Form
of Underwriting Agreement.
|
|
|
|
3.1
|
|
Certificate of Incorporation of Ballantyne of Omaha, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Registration Statement on Form S-8 (File No. 333-139177) filed on December 7, 2006).
|
|
|
|
3.1.1
|
|
Certificate of Amendment to the Certificate of Incorporation of Ballantyne of Omaha, Inc. (incorporated by reference to Exhibit 3.1.1 to the Registrant’s Registration Statement on Form S-8 (File No. 333-139177) filed on December 7, 2006).
|
|
|
|
3.1.2
|
|
Certificate of Amendment to the Certificate of Incorporation of Ballantyne of Omaha, Inc. (incorporated by reference to Exhibit 3.1.2 to the Registrant’s Registration Statement on Form S-8 (File No. 333-139177) filed on December 7, 2006).
|
|
|
|
3.1.3
|
|
Certificate of Amendment to the Certificate of Incorporation of Ballantyne of Omaha, Inc. (incorporated by reference to Exhibit 3.1.3 to the Registrant’s Registration Statement on Form S-8 (File No. 333-139177) filed on December 7, 2006).
|
|
|
|
3.1.4
|
|
Certificate of Amendment of Certificate of Incorporation (incorporated by reference to Exhibit 3.1.4 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-13906) filed on August 7, 2009).
|
|
|
|
3.2
|
|
Ballantyne of Omaha, Inc. Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant’s Registration Statement on Form S-8 (File No. 333-139177) filed on December 7, 2006).
|
|
|
|
3.2.1
|
|
First Amendment to Bylaws of Ballantyne of Omaha, Inc. (incorporated by reference to Exhibit 3.2.1 to the Registrant’s Registration Statement on Form S-8 (File No. 333-139177) filed on December 7, 2006).
|
|
|
|
3.2.2
|
|
Second Amendment to Bylaws of Ballantyne of Omaha, Inc. (incorporated by reference to Exhibit 3.2.1 to the Registrant’s Registration Statement on Form S-8 (File No. 333-139177) filed on December 7, 2006).
|
|
|
|
3.2.3
|
|
Third Amendment to Bylaws of Ballantyne of Omaha, Inc. (incorporated by reference to Exhibit 3.2.3 to the Registrant’s Registration Statement on Form S-8 (File No. 333-139177) filed on December 7, 2006).
|
|
|
|
3.2.4
|
|
Fourth Amendment to Bylaws of Ballantyne of Omaha Inc. (incorporated by reference to Exhibit 99.1 to the Registrant’s Current Report on Form 8-K (File No. 001-13906) filed on May 1, 2007).
|
|
|
|
3.2.5
|
|
Fifth Amendment to Bylaws of Ballantyne Strong, Inc. (incorporated by reference to Exhibit 4.11 to the Registrant’s Registration Statement on Form S-8 (File No. 333-196019) filed on May 16, 2014).
|
|
|
|
4.1*
|
|
Form
of Certificate of Designations of Preferred Stock.
|
|
|
|
4.2
|
|
Form of Indenture.
|
|
|
|
4.3*
|
|
Form
of Debt Security.
|
*
|
To
be filed by amendment or as an exhibit to a document incorporated by reference into this registration statement at a later
date in connection with a specific offering.
|
**
|
To
be filed separately pursuant to Section 305(b)(2) of the Trust Indenture Act of 1939, as amended, if applicable.
|
Item
17. Undertakings
|
a.
|
The
undersigned registrant hereby undertakes:
|
|
1.
|
To
file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
|
|
i.
|
To
include any prospectus required by section 10(a)(3) of the Securities Act of 1933;
|
|
|
|
|
ii.
|
To
reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most
recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information
set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered
(if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low
or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant
to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate
offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement.
|
|
|
|
|
iii.
|
To
include any material information with respect to the plan of distribution not previously disclosed in the registration statement
or any material change to such information in the registration statement;
|
provided
however, that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the registration statement
is on Form S-3 and the information required to be included in a post-effective amendment by those paragraphs is contained in reports
filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange
Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant
to Rule 424(b) that is part of the registration statement.
|
2.
|
That,
for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be
deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.
|
|
3.
|
To
remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold
at the termination of the offering.
|
|
4.
|
That,
for the purpose of determining liability under the Securities Act of 1933 to any purchaser:
|
|
i.
|
Each
prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as
of the date the filed prospectus was deemed part of and included in the registration statement; and
|
|
|
|
|
ii.
|
Each
prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance
on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x) for the purpose of providing the information
required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement
as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract
of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the
issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration
statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such
securities at that time shall be deemed to be the initial bona fide offering thereof.
|
Provided,
however, that no statement made in a registration statement or prospectus that is part of the registration statement or
made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part
of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede
or modify any statement that was made in the registration statement or prospectus that was part of the registration statement
or made in any such document immediately prior to such effective date.
|
5.
|
That,
for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial
distribution of the securities: The undersigned registrant undertakes that in a primary offering of securities of the undersigned
registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the
purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned
registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:
|
|
i.
|
Any
preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant
to Rule 424;
|
|
ii.
|
Any
free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred
to by the undersigned registrant;
|
|
iii.
|
The
portion of any other free writing prospectus relating to the offering containing material information about the undersigned
registrant or its securities provided by or on behalf of the undersigned registrant; and
|
|
iv.
|
Any
other communication that is an offer in the offering made by the undersigned registrant to the purchaser.
|
|
b.
|
The
undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933,
each filing of the registrant’s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange
Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d)
of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to
be a new registration statement relating to the securities offered therein, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof.
|
|
c.
|
The
undersigned registrant hereby undertakes to deliver or cause to be delivered with the prospectus, to each person to whom the
prospectus is sent or given, the latest annual report to security holders that is incorporated by reference in the prospectus
and furnished pursuant to and meeting the requirements of Rule 14a-3 or Rule 14c-3 under the Securities Exchange Act of 1934;
and, where interim financial information required to be presented by Article 3 of Regulation S-X are not set forth in the
prospectus, to deliver, or cause to be delivered to each person to whom the prospectus is sent or given, the latest quarterly
report that is specifically incorporated by reference in the prospectus to provide such interim financial information.
|
|
|
|
|
d.
|
Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling
persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the
opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and
is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment
by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful
defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with
the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
public policy as expressed in the Act and will be governed by the final adjudication of such issue.
|
|
|
|
|
e.
|
If
and when applicable, the Registrant hereby further undertakes to file an application for the purpose of determining the eligibility
of the trustee to act under subsection (a) of Section 310 of the Trust Indenture Act in accordance with the rules and regulations
prescribed by the Securities and Exchange Commission under Section 305(b)(2) of the Trust Indenture Act.
|
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it
meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf
by the undersigned, thereunto duly authorized, in the City of Charlotte, State of North Carolina, on May 28, 2020.
|
Ballantyne
Strong, Inc.
|
|
|
|
|
By:
|
/s/ Mark
D. Roberson
|
|
|
Mark
D. Roberson
|
|
|
Chief
Executive Officer
|
Power
of Attorney
Each
of the undersigned, whose signature appears below, hereby constitutes and appoints Mark D. Roberson and Todd R. Major and each
of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, to do any
and all acts and things and execute, in the name of the undersigned, any and all instruments which said attorney-in-fact and agent
may deem necessary or advisable in order to enable the Company to comply with the Securities Act and any requirements of the SEC
in respect thereof, in connection with the filing with the SEC of this Registration Statement on Form S-3 under the Securities
Act, including specifically but without limitation, power and authority to sign the name of the undersigned to such Registration
Statement, and any amendments to such Registration Statement (including post-effective amendments), and to file the same with
all exhibits thereto and other documents in connection therewith, with the SEC, to sign any and all applications, registration
statements, notices or other documents necessary or advisable to comply with applicable state securities laws, and to file the
same, together with other documents in connection therewith with the appropriate state securities authorities, granting unto said
attorney-in-fact and agent, full power and authority to do and to perform each and every act and thing requisite or necessary
to be done in and about the premises, as fully and to all intents and purposes as the undersigned might or could do in person,
hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute, may lawfully do or cause to be done
by virtue hereof.
Pursuant
to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the
capacities and on the dates indicated.
Signature
|
|
Capacity
in Which Signed
|
|
Date
|
|
|
|
|
|
/s/
Mark D. Roberson
|
|
Chief
Executive Officer
|
|
May
28, 2020
|
Mark
D. Roberson
|
|
(Principal
Executive Officer)
|
|
|
|
|
|
|
|
/s/
Todd R. Major
|
|
Chief
Financial Officer
|
|
May
28, 2020
|
Todd
R. Major
|
|
(Principal
Financial Officer)
|
|
|
|
|
|
|
|
/s/
D. Kyle Cerminara
|
|
Non-Executive
Chairman
|
|
May
28, 2020
|
D.
Kyle Cerminara
|
|
|
|
|
|
|
|
|
|
/s/
Lewis M. Johnson
|
|
Co-Chairman
|
|
May
28, 2020
|
Lewis
M. Johnson
|
|
|
|
|
|
|
|
|
|
/s/
William J. Gerber
|
|
Director
|
|
May
28, 2020
|
William
J. Gerber
|
|
|
|
|
|
|
|
|
|
/s/
Colonel Jack H. Jacobs
|
|
Director
|
|
May
28, 2020
|
Colonel
Jack H. Jacobs
|
|
|
|
|
|
|
|
|
|
/s/
Charles T. Lanktree
|
|
Director
|
|
May
28, 2020
|
Charles
T. Lanktree
|
|
|
|
|
|
|
|
|
|
/s/
Robert J. Roschman
|
|
Director
|
|
May
28, 2020
|
Robert
J. Roschman
|
|
|
|
|
|
|
|
|
|
/s/
Ndamukong Suh
|
|
Director
|
|
May
28, 2020
|
Ndamukong
Suh
|
|
|
|
|
Ballantyne Strong (AMEX:BTN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ballantyne Strong (AMEX:BTN)
Historical Stock Chart
From Sep 2023 to Sep 2024